These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8680399)

  • 1. Protracted post-traumatic confusional state treated with physostigmine.
    Eames P; Sutton A
    Brain Inj; 1995 Oct; 9(7):729-34. PubMed ID: 8680399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Etiology of initially unexplained confusion of excitability in deadly nightshade poisoning with suicidal intent. Symptoms, differential diagnosis, toxicology and physostigmine therapy of anticholinergic syndrome].
    Heindl S; Binder C; Desel H; Matthies U; Lojewski I; Bandelow B; Kahl GF; Chemnitius JM
    Dtsch Med Wochenschr; 2000 Nov; 125(45):1361-5. PubMed ID: 11109424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physostigmine treatment of gamma-hydroxybutyric acid overdose: appropriate or inappropriate use of a reversal agent?
    Dean W
    Mayo Clin Proc; 2000 Aug; 75(8):872-3. PubMed ID: 10943250
    [No Abstract]   [Full Text] [Related]  

  • 4. Observations on the physostigmine syndrome in patients with Alzheimer's disease.
    Wirkowski E; Prohovnik I; Young WL
    J Neuropsychiatry Clin Neurosci; 1991; 3(1):73-5. PubMed ID: 7580177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physostigmine treatment of gamma-hydroxybutyric acid overdose: appropriate or inappropriate use of a reversal agent?
    Mullins ME; Dribben W
    Mayo Clin Proc; 2000 Aug; 75(8):871-2; author reply 872-3. PubMed ID: 10943249
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurological findings in a case of coma secondary to Datura stramonium poisoning.
    Parissis D; Mellidis C; Boutis A; Apostolidis K; Ignatiadis M; Kiosses V; Milonas I
    Eur J Neurol; 2003 Nov; 10(6):745-6. PubMed ID: 14641526
    [No Abstract]   [Full Text] [Related]  

  • 7. Reversal of quetiapine-induced altered mental status with physostigmine: a case series.
    Cole JB; Stellpflug SJ; Ellsworth H; Harris CR
    Am J Emerg Med; 2012 Jul; 30(6):950-3. PubMed ID: 21802878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cholinesterase inhibitor physostigmine for the local treatment of dry mouth: a randomized study.
    Khosravani N; Birkhed D; Ekström J
    Eur J Oral Sci; 2009 Jun; 117(3):209-17. PubMed ID: 19583746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation.
    Taverni JP; Seliger G; Lichtman SW
    Brain Inj; 1998 Jan; 12(1):77-80. PubMed ID: 9483340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physostigmine in the treatment of gamma-hydroxybutyric acid overdose.
    Yates SW; Viera AJ
    Mayo Clin Proc; 2000 Apr; 75(4):401-2. PubMed ID: 10761496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physostigmine reversal of cimetidine--induced mental confusion.
    Mogelnicki SR; Waller JL; Finlayson DC
    JAMA; 1979 Feb; 241(8):826-7. PubMed ID: 762851
    [No Abstract]   [Full Text] [Related]  

  • 12. L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
    Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL
    Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock: study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se).
    Zimmermann JB; Pinder N; Bruckner T; Lehmann M; Motsch J; Brenner T; Hoppe-Tichy T; Swoboda S; Weigand MA; Hofer S
    Trials; 2017 Nov; 18(1):530. PubMed ID: 29126416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
    van Dyck CH; Newhouse P; Falk WE; Mattes JA
    Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upbeat nystagmus as a clinical sign of physostigmine-induced right occipital non-convulsive status epilepticus.
    Neugebauer H; Winkler T; Feddersen B; Pfister HW; Noachtar S; Straube A; Pfefferkorn T
    J Neurol; 2012 Apr; 259(4):773-4. PubMed ID: 21964753
    [No Abstract]   [Full Text] [Related]  

  • 16. [Case report about central effects of physostigmine (author's transl)].
    Eckstein KL; Vincente-Eckstein A
    Anaesthesist; 1980 Jul; 29(7):376-8. PubMed ID: 7425264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
    Imbimbo BP; Verdelli G; Martelli P; Marchesini D
    Dement Geriatr Cogn Disord; 1999; 10(2):139-47. PubMed ID: 10026388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic properties of muscarinic drugs.
    Janowsky DS; Davis JM
    Am J Psychiatry; 2009 Jan; 166(1):110; author reply 110-1. PubMed ID: 19122017
    [No Abstract]   [Full Text] [Related]  

  • 19. Cholinomimetic agents and neurocognitive impairment following head injury: a systematic review.
    Poole NA; Agrawal N
    Brain Inj; 2008 Jul; 22(7-8):519-34. PubMed ID: 18568705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Principles of medical management in chronic open angle glaucoma.
    Sugar HS
    Ann Ophthalmol; 1971 Jun; 3(6):579-86. PubMed ID: 5164431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.